[ CAS No. 956034-07-4 ]

Name: 956034-07-4|2,4-Dichlorofuro[3,2-d]pyrimidine|97%
Brand: Ambeed
SKU: A311543
Price: 26.0 USD
Availability: InStock
Rating: 97 (22 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 956034-07-4

Structure of 956034-07-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 100K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 956034-07-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 956034-07-4 ]

SDS Specification

Alternatived Products of [ 956034-07-4 ]

Product Details of [ 956034-07-4 ]

CAS No. :	956034-07-4	MDL No. :	MFCD11520866
Formula :	C₆H₂Cl₂N₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	OTFDNOQBJWBJJM-UHFFFAOYSA-N
M.W :	189.00 g/mol	Pubchem ID :	45789968
Synonyms :

Calculated chemistry of [ 956034-07-4 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	3.0
Num. H-bond donors :	0.0
Molar Refractivity :	41.82
TPSA :	38.92 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.59 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.14
Log Po/w (XLOGP3) :	2.62
Log Po/w (WLOGP) :	2.53
Log Po/w (MLOGP) :	0.97
Log Po/w (SILICOS-IT) :	2.72
Consensus Log Po/w :	2.2

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.27
Solubility :	0.102 mg/ml ; 0.00054 mol/l
Class :	Soluble
Log S (Ali) :	-3.09
Solubility :	0.155 mg/ml ; 0.000818 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.78
Solubility :	0.0317 mg/ml ; 0.000167 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.33

Safety of [ 956034-07-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 956034-07-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 956034-07-4 ]
Downstream synthetic route of [ 956034-07-4 ]

[ 956034-07-4 ] Synthesis Path-Upstream 1~5

1
[ 956034-06-3 ]
[ 956034-07-4 ]

Yield	Reaction Conditions	Operation in experiment
54%	at 130℃; for 3 h;	To furo[3,2-d]pyrimidine-2,4-diol (7J) (1.52 g, 10 mmol) was added dimethyl aniline (1 mL, 8 mmol), phosphorous oxychloride (0.9 mL, 9.65 mmol) and heated at 130 °C for 3h. The reaction mixture was cooled to room temperature and quenched carefully with ice. The solid obtained was collected by filtration washed with water and dried in vacuum to furnish 2,4- dichlorofuro[3,2-d]pyrimidine (7K) (1.02 g, 54percent) as a light brown solid; mp 107.3 °C; NMR (300 MHz, CDC13) δ 8.08 (d, J= 2.2, 1H), 7.02 (d, J = 2.2, 1H).
48%	at -40℃; for 48 h; Heating / reflux	Furo[3,2-d]pyrimidine-2,4-diol (39 mg, 1.0 eq) was dissolved in POCl₃ (1.8 ml). Mixture was cooled to -40° C. and N,N-diisopropylethylamine (0.45 ml) wad slowly added. Reaction mixture was then heated to reflux for 48 h, then cooled to room temperature Reaction mixture was poured into ice/water. Mixture was extracted with ethyl acetate. The combined organic layers were washed with saturated aq. NaHCO₃, dried (Na₂SO₄) and concentrated to yield 2,4-dichlorofuro[3,2-d]pyrimidine (23 mg, 48percent) which was used in the next reaction without further purification.
48%	at -40℃; for 48 h; Heating / reflux	Furo[3,2-d]pyrimidine-2,4-diol 36 (39 mg, 1.0 eq) was dissolved in POCl₃(1.8 ml). Mixture was cooled to -40 °C and A^V-dusopropylethylamine (0.45 ml) wad slowly added. Reaction mixture was then heated to reflux for 48 h, then cooled to room temperature Reaction mixture was poured into ice/water. Mixture was extracted with ethyl acetate. The combined organic layers were washed with saturated aq. NaHCO₃, dried (Na₂SO₄) and concentrated to yield 2,4-dichlorofuro[3,2-d]pyrimidine 37 (23 mg, 48percent) which was used in the next reaction without further purification.

48%	Stage #1: at -40℃; for 48 h; Heating / reflux Stage #2: at 20℃;	Furo[3,2-d]pyrimidine-2,4-diol 36 (39 mg, 1.0 eq) was dissolved in POCl₃(1.8 ml). Mixture was cooled to -40 ⁰C and iVJV-diisopropylethylamine (0.45 ml) wad slowly added. Reaction mixture was then heated to reflux for 48 h, then cooled to room temperature Reaction mixture was poured into ice/water. Mixture was extracted with ethyl acetate. The combined organic layers were washed with saturated aq. NaHCO₃, dried (Na₂SO₄) and concentrated to yield 2,4-dichlorofuro[3,2-d]pyrimidine 37 (23 mg, 48percent) which was used in the next reaction without further purification.
41%	at -40℃; for 24 h; Reflux	At −40° C., to a solution of compound 30-d (0.86 g, 5.6 mmoL) in phosphorus oxychloride (8 mL) was added N,N-diisopropylethylamine (2 mL), after stirred for 10 minutes, the mixture was refluxed for 24 hours. After cooled to room temperature, the mixture was poured into ice water to quench the reaction, and then extracted with ethyl acetate (50 mL×3). The organic layers were combined, washed with water (20 mL×3) and saturated brine (20 mL) in sequence, then dried over anhydrous sodium sulfate, filtrated, the filtrate was concentrated under reduced pressure. The residue was purified by silica column chromatography (petroleum ether:ethyl acetate-100:1) to give white solid 30-c (430 mg, yield: 41percent). LC-MS (ESI): m/z=189 [M+H]⁺.

Reference： [1] Patent: WO2011/79230, 2011, A2, . Location in patent: Page/Page column 57
[2] Patent: US2008/76758, 2008, A1, . Location in patent: Page/Page column 78
[3] Patent: WO2008/70740, 2008, A1, . Location in patent: Page/Page column 138
[4] Patent: WO2008/73785, 2008, A2, . Location in patent: Page/Page column 165
[5] Journal of Medicinal Chemistry, 2011, vol. 54, # 22, p. 7815 - 7833
[6] Patent: US2015/336982, 2015, A1, . Location in patent: Paragraph 0240; 0246

2
[ 956034-06-3 ]
[ 956034-07-4 ]

Yield	Reaction Conditions	Operation in experiment
87%	at 130℃; for 2 h;	To a mixture of lH-furo[3,2-d]pyrimidine-2,4-dione (3.0 g, 0.020 mol) in NJf- dimethylaniline (2.0 mL, 0.016 mol) was added phosphorous oxychloride (18.0 mL, 0.193 mol) and the resulting mixture heated at 130 °C for 2 h. The resulting black solution was cooled to RT, then carefully quenched with crushed ice and H₂O, then extracted with EtOAc.The organic layer was isolated, dried (MgSO₄) and concentrated in vacuo to give the title compound as a tan solid (3.26 g, 87 percent). ¹H NMR (400 MHz, CDCl₃): δ 7.02 (d, J = 2.2 Hz, 1 H) and 8.08 (d, J = 2.2 Hz, 1 H).

Reference： [1] Patent: WO2008/152394, 2008, A1, . Location in patent: Page/Page column 25; 35
[2] MedChemComm, 2014, vol. 5, # 12, p. 1821 - 1828

3
[ 956034-03-0 ]
[ 956034-07-4 ]

Reference： [1] Patent: WO2011/79230, 2011, A2,
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 22, p. 7815 - 7833
[3] Patent: US2015/336982, 2015, A1,
[4] Patent: WO2008/152394, 2008, A1,

4
[ 956034-04-1 ]
[ 956034-07-4 ]

Reference： [1] Patent: WO2011/79230, 2011, A2,
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 22, p. 7815 - 7833
[3] Patent: US2015/336982, 2015, A1,
[4] Patent: WO2008/152394, 2008, A1,

5
[ 1093066-63-7 ]
[ 956034-07-4 ]

Reference： [1] Patent: WO2011/79230, 2011, A2,
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 22, p. 7815 - 7833
[3] Patent: US2015/336982, 2015, A1,
[4] Patent: WO2008/152394, 2008, A1,

[ 956034-07-4 ] Synthesis Path-Downstream 1~14

1
[ 956034-04-1 ]
[ 956034-07-4 ]

Reference： [1]Patent: WO2011/79230,2011,A2
[2]Journal of Medicinal Chemistry,2011,vol. 54,p. 7815 - 7833
[3]Patent: US2015/336982,2015,A1
[4]Patent: WO2008/152394,2008,A1

2
[ 956034-07-4 ]
[ 1353552-97-2 ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: N-ethyl-N,N-diisopropylamine / methanol / 24 h / 20 °C 2: trifluoroacetic acid / iso-butanol / 12 h / 100 °C 3: hydrogenchloride; iron / ethanol; water / 1 h / 100 °C 4: sodium hydrogencarbonate / water; tetrahydrofuran / 0.5 h / 0 °C

Reference： [1]Current Patent Assignee: HANMI SCIENCE CO LTD - WO2011/162515, 2011, A2

3
[ 956034-07-4 ]
[ 336191-17-4 ]
[ 1372534-58-1 ]

Yield	Reaction Conditions	Operation in experiment
55%	With triethylamine; In 1,4-dioxane; at 25℃; for 12h;	Step A: teri-Butyl 8-(2-chlorofuro[3,2-i/]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-2- carboxylateA mixture of teri-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate (0.83 g, 3.4 mmol, Alfa Aesar), 2,4-dichlorofuro[3,2-i/]pyrimidine (0.65 g, 3.4 mmol, ArkPharm) and TEA (0.96 mL, 6.9 mmol) in 1,4-dioxane (35 mL) was stirred at about 25 C for about 12 h. Water (4 mL) and EtOAc (25 mL) were added and the layers were separated. The organic layer was concentrated under reduced pressure to give teri-butyl 8-(2-chlorofuro[3,2-i/]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-2- carboxylate (1.25 g, 55%): LC/MS (Table 2, Method f) Rt = 2.12 min; MS m/z: 393 (M+H)+.

Reference： [1]Patent: WO2012/48222,2012,A1 .Location in patent: Page/Page column 211

4
[ 956034-07-4 ]
[ 2919-23-5 ]
[ 1372534-30-9 ]

Yield	Reaction Conditions	Operation in experiment
91%	With sodium hydride; In 1,4-dioxane; mineral oil; at 20℃;	General Procedure Y: Nucleophilic displacement of an aryl halide with an alcoholTo a solution of an aryl halide and an appropriate organic solvent (such as 1 ,4-dioxane, DME, n- butanol, THF or DMF, preferably 1,4-dioxane) is added an alcohol (1 to 10 equiv, preferably 1 to 5 equiv) and a base (such as NaH, TEA, DIEA, K2C03, preferably NaH; 1 to 5 equiv, preferably 1 to 1.5 equiv). The resulting mixture is stirred at about 0 to 150 C (preferably about 20 to 80 C) for a period of about 1 h to 24 h (preferably about 4 to 16). The mixture may optionally be concentrated in vacuo to give the target compound. Alternatively, the mixture is optionally filtered through a media (such as silica gel or Celite) which is rinsed with an appropriate solvent (such as EtOAc, 1,4-dioxane, THF, MeCN, DCM, Et20, MeOH, EtOH) and then optionally concentrated in vacuo to give a residue as the target compound. Either the residue or the solution may be optionally partitioned between water and an organic solvent (such as EtOAc, Et20 or DCM). The organic layer is isolated and may optionally be washed in no particular order with water and/or aqueous solutions containing an acid (such as HC1, AcOH or NH4C1) and/or aqueous solutions containing a base (such as NaHC03, Na2C03, NaOH, KOH or NH4OH) and/or aqueous solutions containing an inorganic salt (such as NaCl Na2S03 or Na2S203). The organic solution may then be optionally dried with a drying agent (such as anhydrous MgS04 or Na2S04), filtered and concentrated in vacuo to give the target compound.Illustration of General Procedure YPreparation No.Y.l -Chloro-4-cyclobutoxyfuro[3,2-</]pyrimidineTo a flask was added <strong>[2919-23-5]cyclobutanol</strong> (0.820 mL, 10.5 mmol), 2-chloro-4-cyclobutoxyfuro[3,2- i/]pyrimidine (0.400 g, 2.11 mmol, ArkPharm) and 1,4-dioxane (0.1 mL). To the mixture was added NaH (60% dispersion in mineral oil, 0.102 g, 2.54 mmol). The mixture was stirred at rt overnight. The mixture was extracted with DCM (3 x 5 mL) and water (5 mL). The organic layer was dried over Mg2S04, filtered and concentrated under reduced pressure. Water (20 mL) was added to the residue and the precipitate was collected by filtration and dried in vacuum oven at about 60 C overnight to give 2-chloro-4-cyclobutoxyfuro[3,2-J]pyrimidine (0.4g, 91 %): LC/MS (Table 2, Method c) R, = 2.57 min.; MS m/z: 225 (M+H)+.

Reference： [1]Patent: WO2012/48222,2012,A1 .Location in patent: Page/Page column 186-187

5
[ 956034-07-4 ]
[ 1153949-15-5 ]
C₁₉H₁₉ClN₆O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70%	With tetrakis(triphenylphosphine) palladium⁽⁰⁾; potassium carbonate In 1,4-dioxane; water at 80℃; for 16h; Inert atmosphere;	30 Preparation of Compound 30-b Under nitrogen, to a suspension of compound 5-a (640 mg, 1.65 mmol), compound 30-c (280 mg, 1.49 mmol) and potassium carbonate (720 mg, 5.2 mmol) in 1,4-dioxane (2 mL) and water (6 mL) was added Pd(PPh3)4 (57 mg, 0.05 mmol), the mixture was heated to 80° C. and stirred for 16 hours. The mixture was then concentrated under reduced pressure, the residue was diluted with water (20 mL), extracted with dichloromethane (20 mL×3). The organic layer were combined, washed with water (10 mL×3) and saturated brine (10 mL) in sequence, then dried over anhydrous sodium sulfate, filtrated, the filtrate was concentrated under reduced pressure. The residue was purified by silica column chromatography (petroleum ether:ethyl acetate=3:1) to give light yellow solid 30-b (620 mg, yield: 70%). LC-MS (ESI): nm/z=415 [M+H]+.

Reference： [1]Current Patent Assignee: GUANGZHOU MAXINOVEL PHARMACEUTICALS - US2015/336982, 2015, A1 Location in patent: Paragraph 0240; 0247

6
[ 956034-07-4 ]
[ 1083326-75-3 ]
C₁₃H₁₁ClN₄O₄S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
40 mg	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium carbonate; In 1,4-dioxane; water; at 80℃;Inert atmosphere;	To a reaction flask were added compound 27-c (36 mg, 0.106 mmol), compound 38-b (prepared according to the method disclosed in: WO 2011/079230 A2) (20 mg, 0.106 mmol), PdC12(dppf) (4 mg, 0.005 mmol), 2 N sodium carbonate aqueous solution (0.16 mE, 0.32 mmol, 3.0 equiv.) and 1 ,4-dioxane (1 mE). The mixture was stirred under nitrogen atmosphere at 80 C. overnight. The reaction mixture was concentrated under reduced pressure, and then partitioned between water (15 mE) and dichioromethane (20 mE). The organic phase was separated out, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, to obtain compound 38-a (40 mg). EC-MS (ESI): mlz=354.7 (M+H).

Reference： [1]Patent: US2016/214994,2016,A1 .Location in patent: Paragraph 0225; 0226

7
[ 858131-73-4 ]
[ 956034-07-4 ]
[ 98-80-6 ]
C₃₆H₂₃N₃O [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With tetrakis(triphenylphosphine) palladium⁽⁰⁾; potassium carbonate In tetrahydrofuran; water for 13h; Inert atmosphere; Reflux;	Step2: synthesis of compound (A-5) General procedure: Intermediate product A 20.0 g (50.5 mmol), 4 - phenylboronic Acid 7.39 g (60.6 mmol) and K2CO3 16.8 g (121 mmol), Pd (PPh3) 4 2.92 g (2.53 mmmol) and THF 400 ml, distilled water 200 It was suspended in a stream of nitrogen mlReflux for 13 hours and stirred. After the reaction was cooled and the precipitated solid was filtered. Methanol and the solid several times with water and dried after ssikeun dichloromethane (methylene chloride: MC) and hexane (n-hexane: n-Hex) by recrystallization to obtain a compound (A-5) 18.4g (yield: 83%) was obtained .To the specific compounds according to the embodiment of thepresent invention prepared according to the synthetic methods as describedabove it is shown in Table 1 below.

Reference： [1]Current Patent Assignee: SAMSUNG C&T CORPORATION - KR101648141, 2016, B1 Location in patent: Paragraph 0176; 0192; 0193

8
[ 956034-07-4 ]
[ 114474-28-1 ]
N-(4-(1H-pyrazol-4-yl)phenyl)-2-chlorofuro[3,2-d]pyrimidin-4-amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 100.0℃; for 5.0h;	[0111] A mixture of 2,4-dichlorofuro[3,2-d]pyrimidine (150 mg, 0.79 mmol), 4-(lH- pyrazol-4-yl)aniline (126.3 mg, 0.79 mmol), and diisopropylethylamine (0.28 mL, 1.59 mmol) in DMF (1.59 mL) was heated at 100 C for 5 h. TLC showed the reaction was complete. The mixture was then diluted with water. The resulted yellow precipitate was filtered and washed with water and dried in vacuo to provide 210 mg (85%) title compound which was used directly for next step reaction without further purification.

Reference： [1]Patent: WO2016/210330,2016,A1 .Location in patent: Paragraph 0110-0111

9
[ 956034-07-4 ]
[ 325775-44-8 ]
tert-butyl 3-(((2-chloro-furo[3,2-d]pyrimidin-4-yl)amino)methyl)azetidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
83.5%	With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran;Reflux;	Step 1: preparation of tert-butyl 3-(((2-chloro-furo[3,2-d]pyrimidin-4-yl)amino) methyl)azetidine-1-carboxylate (0257) (0258) 2,4-Dichloro-furo[3,2-d]pyrimidine (189 mg, 1 mmol) and <strong>[325775-44-8]tert-butyl 3-(aminomethyl)azetidine-1-carboxylate</strong> (186 mg, 1 mmol) were dissolved in tetrahydrofuran (20 mL), followed by the addition of N,N-diisopropylethylamine (258 mg, 2 mmol). The reaction solution was reacted under reflux overnight, then cooled to room temperature, and concentrated. The residue was added with water (20 mL), and extracted with ethyl acetate (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 6 : 1), to give a white solid (283 mg). Yield: 83.5%. MS (ESI, m/z): [M+H]+: 339.1.

Reference： [1]Patent: EP3048105,2016,A1 .Location in patent: Paragraph 0257; 0258

10
[ 956034-07-4 ]
[ 1228947-14-5 ]
N-(3-methylisothiazol-5 yl)-4-(((1r,4r)-4-morpholinocyclohexyl)oxy)furo[3,2-d]pyrimidin-2-amine [ No CAS ]

Reference： [1]Patent: WO2017/205766,2017,A1

11
[ 956034-07-4 ]
[ 1228947-14-5 ]
2-chloro-4-(((1r,4r)-4-morpholinocyclohexyl)oxy)furo[3,2-d]pyrimidine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
60%		A mixture of(lr,4r)-4-morpholinocyclohexan-1-ol (0.53 g, 2.9 mmol, 1.1 eq) in 5.0 mL of THF was prepared and 60% NaH (0.56 g, 14 mmol, 5.3 eq) was added. The reaction mixture was stirred at room temperature for 30 mm and 2,4-dichlorofuro[3,2-djpyrimidine (0.50 g, 2.6 mmol, 1.0 eq) was added and the resulting mixture was heated at 60 C for 3 hr. The reaction was cooled to room temperature and quenched with saturated aqueous ammonium chloride. The quenched mixture was rotary evaporated and purified on normal phase Combi-Flash using a 40 g column and eluting with a gradient of 0-20% MeOH/CH2C12 in 10 mm. The product containing fractions were combined and rotary evaporated to give 2-chloro-4-(((lr,4r)-4- morpholinocyclohexyl)oxy)furo[3,2-djpyrimidine (0.59 g, 1.7 mmol, 60% yield) as a white solid. LC-MS:M+H=338.0

Reference： [1]Patent: WO2017/205766,2017,A1 .Location in patent: Paragraph 00447

12
[ 956034-07-4 ]
[ 89088-69-7 ]
2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
59%	With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; for 24h;Reflux;	To a solution of 2,4-dichlorofuro[3,2-d]pyrimidine (la) (0.71 g, 3.74 mmol; CAS 956034- 07-4) in 2-Propanol (20 mL) was added DIPEA (1.63 mL, 9.36 mmol), <strong>[89088-69-7]1-methyl-1H-imidazol-4-amine hydrochloride</strong> (0.5 g, 3.74 mmol) and heated at reflux for 24 h. The reaction mixture was concentrated in vacuum to dryness and the residue obtained was triturated with water. The solid obtained was collected by filtration and dried in vacuum to afford 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (lb) (550 mg,59 % yield) as brown solid; NMR (300 MHz, DMSO-^) delta 10.89 (s, 1H, D20exchangeable), 8.35 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 3.71 (s, 3H); MS (ES+): 250.3 (M+l), 272.3, 274.3 (M+Na), (ES-): 248.2 (M-l).
59%	With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; for 24h;Reflux;	To a solution of 2,4-dichlorofuro[3,2-d]pyrimidine (la) (0.71 g, 3.74 mmol; CAS 956034- 07-4) in 2-Propanol (20 mL) was added DIPEA (1.63 mL, 9.36 mmol), <strong>[89088-69-7]1-methyl-1H-imidazol-4-amine hydrochloride</strong> (0.5 g, 3.74 mmol) and heated at reflux for 24 h. The reaction mixture was concentrated in vacuum to dryness and the residue obtained was triturated with water. The solid obtained was collected by filtration and dried in vacuum to afford 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (lb) (550 mg,59 % yield) as brown solid; NMR (300 MHz, DMSO-^) delta 10.89 (s, 1H, D20exchangeable), 8.35 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 3.71 (s, 3H); MS (ES+): 250.3 (M+l), 272.3, 274.3 (M+Na), (ES-): 248.2 (M-l).

Reference： [1]Patent: WO2018/232094,2018,A1 .Location in patent: Page/Page column 89
[2]Patent: WO2018/232094,2018,A1 .Location in patent: Page/Page column 89; 167

13
[ 956034-07-4 ]
[ 1890954-24-1 ]
[ 2313366-52-6 ]

Yield	Reaction Conditions	Operation in experiment
86%	Stage #1: 2,4-dichloro-furo[3,2-d]pyrimidine With lithium diisopropyl amide In tetrahydrofuran at -60℃; for 1h; Stage #2: 2,6-difluoro-3,5-dimethoxybenzene(meth)aldehyde In tetrahydrofuran at -60℃; for 2h;

Reference： [1]Current Patent Assignee: ADVENT PHARMA; ADVNET PHARMA - WO2019/80878, 2019, A1 Location in patent: Page/Page column 62; 63

14
[ 832114-05-3 ]
[ 956034-07-4 ]
tert-butyl 3-(2-chlorofuro[3,2-d]pyrimidin-4-yl)benzylcarbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	With potassium phosphate; tris-(dibenzylideneacetone)dipalladium⁽⁰⁾; tricyclohexylphosphine In 1,4-dioxane; water at 120℃; for 1.5h; Inert atmosphere;	1 Step-l : Preparation of /ert-butyl 3-(2-chlorofuro[3,2-d]pyrimidin-4-yl)benzylcarbamate (36b) Compound 36b was prepared according to the procedure reported in step-3 of Scheme- 1 from 2,4-dichlorofuro[3,2-d]pyrimidine (36a) (3 g, 15.87 mmol; CASNo. 956034-07-4) in dioxane (100 mL) using /er/-butyl 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzylcarbamate (3b) (3.78 g, 11.34 mmol), tripotassium phosphate (8.31 mL, 24.94 mmol, 3 M aqueous solution) in water (1 mL), tricyclohexylphosphine (0.95 g, 3.38 mmol) and Pd2(dba)3 (1.04 g, 1.13 mmol) in argon atmosphere and heating in an oil bath at 120 °C for 1.5 h. This gave after workup and purification by flash column chromatography [silica (40 g), eluting with EtOAc in hexane from 0-70%] /er/-butyl 3-(2-chlorofuro[3,2-d]pyrimidin-4- yl)benzylcarbamate (36b) (2.65 g, 65 % yield) as a white solid; NMR (300 MHz, DMSO- de) d 8.74 (d, J = 2.3 Hz, 1H), 8.29 (d, J = 7.5 Hz, 2H), 7.66 - 7.47 (m, 3H), 7.33 (d, J = 2.3 Hz, 1H), 4.26 (d, J = 6.2 Hz, 2H), 1.42 (s, 9H); MS (ES-): 358.3 & 360.3 (M-l).

Reference： [1]Current Patent Assignee: BIOCRYST PHARM INC; BIOCRYST PHARMACEUTICALS INC - WO2019/195720, 2019, A1 Location in patent: Page/Page column 166

Related Products

Historical Records

Related Functional Groups of
[ 956034-07-4 ]

Chlorides

[ 655255-09-7 ]

4-Chlorofuro[3,2-d]pyrimidine

Similarity: 0.90

[ 280582-25-4 ]

2,4-Dichloro-5-ethoxypyrimidine

Similarity: 0.75

[ 19646-07-2 ]

2,4-Dichloro-5-methoxypyrimidine

Similarity: 0.75

[ 39876-88-5 ]

4-Chlorobenzofuro[3,2-d]pyrimidine

Similarity: 0.74

[ 91183-17-4 ]

5-(Benzyloxy)-2,4-dichloropyrimidine

Similarity: 0.71

Related Parent Nucleus of
[ 956034-07-4 ]

Other Aromatic Heterocycles

[ 655255-09-7 ]

4-Chlorofuro[3,2-d]pyrimidine

Similarity: 0.90

[ 39876-88-5 ]

4-Chlorobenzofuro[3,2-d]pyrimidine

Similarity: 0.74

[ 39551-54-7 ]

2,4-Dichloropyrido[3,2-d]pyrimidine

Similarity: 0.58

[ 76780-96-6 ]

2,4-Dichloro-6,7,8,9-tetrahydro-5H-cyclohepta[d]pyrimidine

Similarity: 0.54

[ 1260890-53-6 ]

Oxazolo[5,4-c]pyridin-2-amine

Similarity: 0.54

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 956034-07-4 ]

Quality Control of [ 956034-07-4 ]

Related Doc. of [ 956034-07-4 ]

Product Details of [ 956034-07-4 ]

Calculated chemistry of [ 956034-07-4 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 956034-07-4 ]

Application In Synthesis of [ 956034-07-4 ]

[ 956034-07-4 ] Synthesis Path-Upstream 1~5

[ 956034-07-4 ] Synthesis Path-Downstream 1~14

Related Functional Groups of [ 956034-07-4 ]

Chlorides

Related Parent Nucleus of [ 956034-07-4 ]

Other Aromatic Heterocycles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 956034-07-4 ]

Related Parent Nucleus of
[ 956034-07-4 ]